Intrathecal Methotrexate Versus Central Nervous System Leukemia
- 1 January 1984
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Drug Delivery
- Vol. 1 (2) , 157-167
- https://doi.org/10.1089/cdd.1984.1.157
Abstract
This article summarizes studies conducted in children with acute lymphoblastic leukemia (ALL) who received intrathecal methotrexate (IT MTX) to prevent or treat central nervous system (CNS) leukemia.(1-7) To better understand the pharmacologic requirements of intrathecal chemotherapy directed against CNS leukemia, this report begins with a review of the pathophysiology of CNS leukemia and the clinical aspects of this disease manifestation that influence IT MTX therapy. The pharmacokinetics of IT MTX are then presented and the review is concluded with observations on the importance of the dosage regimen.This publication has 12 references indexed in Scilit:
- Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen.Journal of Clinical Oncology, 1983
- The ninth annual david karnofsky lecture.Treatment of acute lymphocytic leukemiaCancer, 1979
- Proliferative kinetics of the leukemic cells in meningeal leukemiaCancer, 1978
- Proliferative kinetics of central nervous system (CNS) leukemiaCancer, 1975
- The incidence of central nervous system leukemia in adults with acute leukemiaCancer, 1974
- Factors That Influence the Appearance of Central Nervous System LeukemiaBlood, 1973
- The central nervous system in childhood leukemia: I. The arachnoidCancer, 1973
- Factors in Pathogenesis of Central-nervous-system LeukaemiaBMJ, 1972
- Studies on the Use of "Prophylactic" Intrathecal Amethopterin in Childhood LeukemiaBlood, 1970